Wednesday, November 26, 2014

Sunstar Expands Horizons to Enhance Efficiency Throughout the Dental Practice



Noted innovator launches efficiency-enhancing “game changers” in both hygiene and periodontology
Chicago, IL, November 25, 2014 —Leading oral healthcare products manufacturer Sunstar Americas will use the Greater New York Dental Meeting to showcase efficiency-enhancing innovations for not only its traditional area of hygiene care, but for periodontal procedures as well. Looking to augment its longstanding heritage as a dental hygiene innovator, Sunstar will spotlight its new Butler® ProphyciencyTM disposable prophy angles, the industry’s only prophy angles that clean and polish without paste. In addition, the company will expand its reach within the dental practice with its launch of a revolutionary, easy-to-handle bone grafting solution aptly named GUIDOR® easy-graft® alloplastic bone grafting system.
Butler® ProphyciencyTM disposable prophy angles, the latest breakthrough in professional dental hygiene pioneered by Sunstar, represent a truly smarter way to clean. They can save hygienists considerable time by eliminating the need to refill the cup in the prophy angle as well as the need for the patient to rinse during a cleaning, by providing much better visibility during cleaning, and by simplifying cleanup between patients due to the lack of paste splatter or mess.
Moreover, Butler® ProphyciencyTM delivers exceptionally versatile cleaning efficacy. Its unique ButlerBloomTM. Contouring Cup is designed to effectively clean and polish interproximally, subgingivally and on all facial and lingual tooth surfaces. It adapts better to follow contours on all tooth surfaces, and it transitions easily from tooth to tooth. One study revealed that 78% of patients who received a ProphyciencyTM prophylaxis preferred it to the traditional procedure. A related study revealed that 71% of dental professionals who used ProphyciencyTM felt that it would be beneficial to their polishing procedure and patient care. In addition, clinical research indicates that ProphyciencyTM delivers significantly superior stain removal than the leading prophy angle brand used in combination with the leading prophy paste.
GUIDOR® easy-graft® is an ultra-efficient bone grafting solution being introduced by Sunstar into the
North American market after years of success in overseas markets. It is a fully resorbable, synthetic bone graft substitute that will appeal to clinicians who seek stability, osteoconductivity and control of placement. With over 250,000 applications worldwide, GUIDOR® easy-graft® is a complete system that can be trusted to predictably and efficiently handle all socket preservation and immediate implant needs.
Each GUIDOR® easy-graft® system is composed of beta-tricalcium phosphate granules coated with a polylactide polymer that are mixed with an N-methyl-2-pyrrolidone liquid activator called BioLinker® to form a permeable, moldable material that hardens to form a stable, porous scaffold. This unique combination of materials in GUIDOR® easy-graft® provides the foundation for exceptionally easy preparation, dispensing and shaping. The porosity of the granule supports material resorption and bone regeneration. A majority of clinicians surveyed said they use GUIDOR® easy-graft® because preparation and placement are simpler and faster than other bone graft materials and because use it does not require a membrane in many cases.
“We feel these two innovations will have a dramatic impact on the efficiency of our valued customers,” said Aaron Pfarrer, Senior Director of Marketing and Professional Relations for Sunstar. “Butler® ProphyciencyTM builds on our rich heritage of enhancing the efficacy and convenience of hygiene care, while GUIDOR® easy-graft® will enable us to bring the same degree of ingenuity to periodontics that we have been bringing to dental hygiene for decades.”
The Butler® ProphyciencyTMand GUIDOR® easy-graft® product lines, and all other Sunstar Americas products, can be viewed at Booth #3828 at the Greater New York Dental Meeting November 30 through December 3, 2014. Additional information about Sunstar Americas professional dental products can be found at us-professional.gumbrand.com.
###
Sunstar Americas
Chicago-based Sunstar Americas, Inc. is a member of the Sunstar Group of companies and provides quality oral care products under the Butler®, GUM® and GUIDOR® brands. Sunstar, a global organization headquartered in Switzerland, has been providing research-based products and services in 90 countries for over 80 years. Sunstar’s mission is to enhance the health and well-being of people everywhere via its four business areas: mouth and body, health and beauty, healthy home, and safety and technology. Please visit us at www.sunstar.com.

Tuesday, November 25, 2014

Join me at the Greater NY Dental Meeting

I will be presenting lectures at the Greater New York Dental Meeting on Sunday at 1pm and 3pm on Accelerated Orthodontics for the GP in the Propel booth 418. On Monday at 9:45am Digital Technology, Managing The Fastest Area of Growth In Your Practice on securing your office data. That lecture will take place on the exhibit floor.

PeriRx, LLC Covering all Bases During Its Greater New York Dental Meeting Debut

 
Company’s Launch of its SaliMark™ OSCC Salivary Test for Oral Cancer
Includes Free CE Course, Free Industry Reception and Free Test Kit

Broomall, PA – November 24,  2014 – PeriRx LLC, a premier developer of breakthrough, non-invasive, oral diagnostic technology, will be making its national debut at booth #1506 during the Greater New York Dental Meeting from Sunday, November 30th  to  Wednesday, December 3rd at the Jacob K. Javits Convention Center in New York City.
“We’re very excited to be making our official debut at the Greater New York Dental Meeting,” said Stephen M. Swanick, CEO and founder of PeriRx, LLC. “We’re using a variety of ways to engage with members of the dental community and tell them about SaliMark™ OSCC, the most clinically-advanced salivary test for oral cancer, which is scheduled to ship before the end of the year.”
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles.  What’s more, more than a decade of National Institute of Dental and Craniofacial Research and National Institute of Health- supported research make SaliMark™ OSCC the world’s most scientifically-validated molecular DNA biomarker test for oral squamous cell carcinoma.
In addition to exhibiting at booth #1506, PeriRx will be introducing SaliMark OSCC in the following ways:
·       Free CE Course: “Salivary Testing for Early Diagnosis of Oral Cancer" (course code #3240) will be given on Sunday November 30th, 2014 at 9am.  Attendees will receive $15.00 lunch voucher at the end of the course which can be used at any Javits restaurant.  Course presenters are Jack Martin, MD, Neil Gottherer, DDS and Mark Cohen, DDS.

·       Free Industry Reception: This press conference for the entire industry will feature some late-breaking research data presented by the PeriRx executive team that further confirms the efficacy of SaliMark OSCC for early oral cancer detection. Several other industry leaders are expected to say a few words regarding the importance of these latest findings.  This free event will take place on Monday, December 1st from 3:00 - 4:00 PM at booth # 5430.
-more-

·       Free SaliMark OSCC Test Kit: Any dental practice owner who pre-registers and creates a PeriRx online ordering account, will receive one free SaliMark test Kit in order to get familiar with the test, the protocol and the lab results. Simply visit http://perirxsecure.com/register.php to register your practice and set up an account.* 
For more information about PeriRx, LLC or its SaliMark OSCC salivary test for oral cancer, visit www.PeriRx.com, call 610-544-3500 or send an email to info@PeriRx.com.
* Not yet approved for sale in the state of New York. New York practice owners who register online will be kept on file and notified immediately when SaliMark is approved for sale and use in their state.

About SaliMark™ OSCC
Development of this simple-to-use, painless and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and pre-validation work conducted by Dr. David Wong of the University of California at Los Angeles. The SaliMark OSCC test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.  Recently, the SaliMark OSCC test underwent a PRoBE (prospective-specimen-collection, retrospective-blinded-evaluation) design study which is the most rigorous biomarker validation available. In addition, PeriRx successfully completed a validation of the mRNA markers at the University of Michigan, Michigan State University and the St. Johns Providence Health System in Detroit.
About PeriRx LLC:
Based in Broomall, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, non-invasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.  
The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO and founder Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.
PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.

Monday, November 24, 2014

Visual acuity of dentists in their respective clinical conditions

, Volume 18, Issue 9, pp 2055-2058
Date: 31 Jan 2014

Abstract

Objectives

This study examined the impact of age and magnification on the near visual acuity of dentists in their private practice under simulated clinical conditions.

Materials and methods

Miniaturized visual tests were fixed in posterior teeth of a dental phantom head and brought to 31 dentists in their respective private practice. The visual acuity of these dentists (n = 19, ≥40 years; n = 12, <40 300="" a="" acuity="" additional="" and="" available.="" b="" c="" choice="" clinical="" conditions:="" distance="" following="" free="" if="" in="" light="" loupe="" measured="" mm="" natural="" nbsp="" of="" p="" setting="" source="" the="" under="" visual="" was="" years="">

Results

The visual acuity under the different clinical conditions varied widely between individuals. The older group of dentists had a lower median visual acuity value under all clinical conditions. This difference was highly significant for natural visual acuity at a free choice of distance (p < 0.0001). For younger dentists (<40 acuity="" be="" by="" class="a-plus-plus" could="" distance="" em="" eye-object="" improved="" nbsp="" reducing="" significantly="" the="" visual="" years="">p
= 0.001) or by using loupes (p = 0.008). For older dentists (≥40 years), visual acuity could be significantly improved by using loupes (p = 0.0005).

Conclusions

Visual performance decreased with increasing age under the specific clinical conditions of each dentist’s private practice. Magnification aids can compensate for visual deficiencies.

Clinical relevance

The question of whether findings obtained under standardized conditions are valuable for the habitual setting of each dentist’s private practice seems clinically relevant.

Friday, November 21, 2014

Influence of daily immersion in denture cleanser on multispecies biofilm

, Volume 18, Issue 9, pp 2179-2185
Date: 04 Mar 2014

Abstract

Objective

The aim of this study was to evaluate the effect of daily exposure to a denture cleanser on a multispecies biofilm.

Materials and methods

Multispecies biofilms (five bacteria and Candida albicans) were developed for 64.5 h on acrylic resin specimens and randomized into control and experimental groups. In the experimental group, biofilms were immersed in denture cleanser for 3 min/day for seven consecutive days. In the control group, the biofilms were developed with no treatment for the same period. Biofilms from both groups were collected after 1, 4, and 7 days and analyzed for the number of microorganisms and polysaccharide concentrations. Scanning electron microscopy (SEM) and confocal microscopy (CLSM) analyses were performed.

Results

The total microorganism counts and bacterial populations were lower in the experimental group compared to the control group for all of the periods evaluated. However, the C. albicans counts continuously increased in all of the cleanser-exposed biofilms, with abundant hyphae forms on SEM and CLSM images. The polysaccharide concentration was significantly higher in the experimental group after 7 days.

Conclusions

Daily exposure of a multispecies biofilm to a denture cleanser reduces the number of total microorganisms but favors C. albicans development.

Clinical relevance

Daily use of denture cleanser is an effective method for controlling bacteria in biofilm, but it can potentially select C. albicans, an important etiological agent of oral candidosis.

Thursday, November 20, 2014

Six-month results following treatment of aggressive periodontitis with antimicrobial photodynamic therapy or amoxicillin and metronidazole

, Volume 18, Issue 9, pp 2129-2135
Date: 04 Feb 2014

Abstract

Objective

The use of antibacterial photodynamic therapy (aPDT) additionally to scaling and root planing (SRP) has been shown to positively influence the clinical outcomes. However, at present, it is unknown to what extent aPDT may represent a potential alternative to the use of systemic antibiotics in nonsurgical periodontal therapy in patients with aggressive periodontitis (AP). The aim of this study was to evaluate the outcomes following nonsurgical periodontal therapy and additional use of either aPDT or amoxicillin and metronidazole (AB) in patients with AP.

Material and methods

Thirty-six patients with AP displaying at least three sites with pocket depth (PD) ≥6 mm were treated with SRP and either systemic administration of AB for 7 days or with two episodes of aPDT. The following clinical parameters were evaluated at baseline and at 6 months: plaque index (PI), bleeding on probing (BOP), PD, gingival recession (GR) and clinical attachment level (CAL).

Results

Thirty-five patients have completed the 6-month evaluation. At 6 months, mean PD was statistically significantly reduced in both groups (from 5.0 ± 0.8 to 3.0 ± 0.6 mm with AB and from 5.1 ± 0.5 to 3.9 ± 0.8 mm with aPDT (p < 0.001)). AB yielded statistically significantly higher improvements in the primary outcome parameter PD (p < 0.001) when compared to aPDT. The number of pockets ≥7 mm was reduced from 141 to 3 after AB (p < 0.001) and from 137 to 45 after aPDT (p = 0.03). Both therapies resulted in statistically significant reductions in all parameters compared to baseline.

Conclusion

While both treatments resulted in statistically significant clinical improvements, AB showed statistically significantly higher PD reduction and lower number of pockets ≥7 mm compared to aPDT.

Clinical relevance

In patients with AP, the two times application of aPDT in conjunction with nonsurgical periodontal therapy cannot be considered an alternative to the systemic use of amoxicillin and metronidazole.

Wednesday, November 19, 2014

Microbial contamination of laboratory constructed removable orthodontic appliances

, Volume 18, Issue 9, pp 2193-2202

Abstract

Objectives

This study aims to determine whether laboratory constructed removable orthodontic appliances are free from microbial contamination prior to clinical use and to evaluate the dental hospital cross-infection procedures to ensure that patient-derived contamination does not enter the construction process, thereby propagating a cycle of cross-contamination.

Materials and methods

The construction process of removable orthodontic appliances from three individuals was evaluated at every stage, from impression to final delivery of the appliance using molecular microbiological techniques. The bacterial profiles at each stage of appliance construction were obtained using denaturing gradient gel electrophoresis, along with the bacterial profiles of the three participants’ saliva. This enabled the bacterial profiles found at each stage of construction to be compared directly with the saliva of the person for whom the appliance was being constructed. Bacteria were identified at each stage using 16S rDNA PCR amplification and sequence phylogeny.

Results

There was no evidence of bacterial cross-contamination from patients to the laboratory. The current process of disinfection of impression appears to be adequate. Contamination was found on the final removable appliances (0.97 × 102–1.52 × 103 cfu ml−1), and this contamination occurred from within the laboratory itself.

Conclusions

Every effort is made to reduce potential cross-infection to patients and dental professionals. Newly constructed removable appliances were shown not to be free from contamination with bacteria prior to clinical use, but this contamination is environmental. Further studies would be required to determine the level of risk this poses to patients.

Clinical significance

Dental professionals have a duty of care to minimise or eradicate potential risks of cross-infection to patients and other members of the team. To date, much less attention has been paid to contamination from the orthodontic laboratory, so contamination and infection risks are unknown.

Tuesday, November 18, 2014

Effect of periodontal treatment on peak serum levels of inflammatory markers

, Volume 18, Issue 9, pp 2113-2121

Abstract

Background and objective

Some subjects with untreated periodontitis exhibit elevated levels of distinct inflammatory markers in serum. The aim of the study was to assess whether nonsurgical periodontal therapy changes the levels of these markers and lowers these peaks.

Methods

Forty periodontally diseased subjects received nonsurgical periodontal therapy (full-mouth scaling and root planing within 48 h) with either adjunctive systemic amoxicillin and metronidazole (n = 19) or placebo (n  = 21). Serum samples, obtained at baseline (BL) and 3 months after treatment (M3), were evaluated for 15 cytokines and 9 acute-phase proteins using the Bio-Plex bead array multianalyte detection system. For each analyte, peak values were defined as greater than the mean + 2 standard deviations (SD) of measurements found in 40 periodontally healthy persons. Proportions were compared using Fisher’s exact test.

Results

At M3, a significantly better primary clinical outcome (persisting pockets of >4 mm with bleeding on probing) was obtained in patients treated with scaling and root planing plus antibiotics compared to those receiving placebo (3.3 ± 5.1 vs. 6.8 ± 7.8 pockets per patient, p  < 0.05). The levels of cytokines and acute-phase proteins of periodontitis patients were usually below the mean + 2 SD threshold of healthy persons. However, values above threshold were found in some individuals. Eleven patients showed a peak value of one analyte, and seven patients showed two peaks. In the remaining 12 patients, between three and ten analytes showed peak values. Therapy greatly reduced the number of subjects with four or more peaks (BL, 11 subjects; M3, 1 subject, p = 0.003). With regards to the reduction of peaks, no specific benefit of adjunctive antibiotics could be seen.

Conclusion

Subjects with untreated periodontitis may show high peaks for several inflammatory markers in serum simultaneously. Nonsurgical periodontal treatment with or without antibiotics reduced most of these peak levels.

One-sentence summary

Nonsurgical periodontal treatment with or without antibiotics reduced peak levels of several inflammatory markers in serum of subjects with periodontitis.

Monday, November 17, 2014

New Web Tool Provides Immediate Repair Requests, Online Education and Training for All StarDental® Customers


DentalEZ® Group Introduces the 360° Customer Care Program
  
Malvern, PA (November 13, 2014) – DentalEZ® Group, a supplier of integrated products and services for dental health professionals worldwide, is pleased to introduce its new 360° Customer Care Program, a comprehensive online customer service tool for all StarDental® customers.

Located at www.dentalez.com/360customercare, the new 360° Customer Care Program is an extension of DentalEZ Group’s professional and preventive maintenance and repair support program. Geared toward all dental professionals and distribution partners, the 360° Customer Care Program provides a newly designed repair support program that provides instantaneous labels for repair requests as well as a comprehensive collection of educational and training resources for all StarDental products.   

A key feature of the 360° Customer Care Program is a new repair request form that provides an efficient, no-hassle method of requesting repairs on any and all StarDental products. Designed for a fast, user-friendly experience, the repair request form provides convenient drop down menus for identifying and immediately reporting the specific product, repair type and problem. Users simply fill in the information, print the repair request form and press the submit button. A prepaid UPS label is available to be shipped along with the repair form and product being sent for repair.

In addition to the new repair request form, visitors of the 360° Customer Care Program have access to the following pertaining to StarDental’s full line of products:

·       Maintenance and repair videos
·       Instructional manuals
·       Product brochures
·       Maintenance check sheets
·       Warranty registration forms

For more information on DentalEZ’s new 360° Customer Care Program, please visit www.dentalez.com/360customercare.

About DentalEZ® Group

DentalEZ® Group is committed to advancing the practice of dentistry through innovative products and services. Encompassing six distinct product brands — StarDental®, DentalEZ®, CustomAir®, RAMVAC®, NevinLabs and Columbia Dentoform® — DentalEZ® Group manufactures everything in the operatory, from handpieces to chairs to vacuum systems to dental simulation models, creating a complete line of products to elevate the health, comfort
and efficiency of the dental operatory. For more information, please visit
www.dentalez.com.

Friday, November 14, 2014

Intra-oral Adjustment/Polishing for Zirconia and Lithium Disilicate

  Garrison Dental Solutions  
 
INTRODUCING a NEW product from Garrison!
 
   

Join us on Facebook!Watch us on YouTube!
 
   

Join us on Facebook!Watch us on YouTube!
 
 
Intra-oral Adjustment/Polishing for Zirconia and Lithium Disilicate
eZr™ is a three-step diamond impregnated polishing system that polishes zirconia and e-max®† to smooth.
  • Enables easy and safe adjustment for zirconia and lithium disilicate.
  • Proprietary diamond impregnated polisher reduces possibility of chipping and microfracturing.
  • Provides an unparalleled smoothly polished occlusal surface, eliminating abrasiveness to opposing dentition.
  • Prevents over-heating that could lead to premature failure.
  • Eliminates the need for polishing paste, reducing overall cost per procedure.
† Not a product or trademark of Garrison Dental Solutions, LLC.
 
 
Complete system kit, 2 grinders and 6 polishers
$159

Thursday, November 13, 2014

Comparison of microtensile bond strength of a resin composite to enamel conditioned by acid etching and Er,Cr:YSGG laser in human primary teeth

 

Abstract

Aim

This study was designed to compare the bond strength of composite resin restorations on the buccal surface of primary human canine after conditioning by conventional acid etching and Er,Cr:YSGG laser.

Methods

Twenty sound primary canines were cut buccolingually into two halves and each half was randomly placed in Er,Cr:YSGG laser or acid etch group. The samples in the acid etch group were etched with 37 % phosphoric acid for 30 s. The samples in the laser group were prepared by Er,Cr:YSGG laser. The G6-Tips and 600 µm diameter were used with a 1.5 W of power output, pulse duration of 140 µs and repetition rate of 20 Hz. The bonding agent was applied on the buccal surface of each sample and layers of resin composite were placed. The samples’ bond strengths were evaluated by a microtensile test instrument.

Results

The mean of microtensile bond strength was 18.55 ± 6.41 in the laser group and 24.62 ± 5.56 in acid etch group. Microtensile bond strength achieved by laser conditioning was significantly lower than microtensile bond strength achieved by the conventional acid etching. Statistics To compare the results between the acid etch and laser group, the paired t test was performed (p value < 0.001).

Conclusion

Conditioning enamel in primary teeth by Er,Cr:YSGG laser, cannot be used as an alternative method for acid etching and cannot substitute this conventional method.

Wednesday, November 12, 2014

The effect of intermittent use of occlusal splint devices on sleep bruxism: a 4-week observation with a portable electromyographic recording device

Matsumoto, H., Tsukiyama, Y., Kuwatsuru, R. and Koyano, K. (2014), The effect of intermittent use of occlusal splint devices on sleep bruxism: a 4-week observation with a portable electromyographic recording device. Journal of Oral Rehabilitation. doi: 10.1111/joor.12251

Summary

This randomised controlled study investigated the effect of intermittent use of occlusal splints on sleep bruxism compared with that of continuous use by measuring masseter muscle electromyographic activity using a portable electromyographic recording system. Twenty bruxers were randomly allocated to the continuous group and intermittent group. Subjects in the continuous group wore stabilisation splints during sleep for 29 nights continuously, whereas those in the intermittent group wore splints during sleep every other week, that is they used splints on the 1st–7th, 15th–21st and 29th nights. Electromyographic activity of the masseter muscle during sleep was recorded for the following six time points: before (baseline), immediately after, and 1, 2, 3 and 4 weeks after the insertion of a stabilisation splint. The number of nocturnal masseter electromyographic events, duration and the total activity of sleep bruxism were analysed. In the continuous group, nocturnal masseter electromyographic events were significantly reduced immediately and 1 week after the insertion of the stabilisation splint, and duration was reduced immediately after the insertion (P < 0·05, Dunnett's test), but no reduction was observed at 2, 3 and 4 weeks after insertion. In the intermittent group, nocturnal masseter electromyographic events and duration were significantly reduced immediately after and also 4 weeks after insertion of the stabilisation splint (P < 0·05, Dunnett's test). The obtained results of the present exploratory trial indicate that the intermittent use of stabilisation splints may reduce sleep bruxism activity for a longer period compared with that of continuous use.

Tuesday, November 11, 2014

‘Treasure in saliva’ may reveal deadly diseases early enough to treat them, UCLA scientists report

http://newsroom.ucla.edu/releases/treasure-in-saliva-may-reveal-deadly-diseases-early-enough-to-treat-them-ucla-scientists-report

UCLA research could lead to a simple saliva test capable of diagnosing — at an early stage — diabetes and cancer, and perhaps neurological disorders and autoimmune diseases.
The study, the most comprehensive analysis ever conducted of RNA molecules in human saliva, reveals that saliva contains many of the same disease-revealing molecules that are contained in blood. It was published online today by the peer-reviewed journal Clinical Chemistry and will be published in the journal’s January 2015 special print issue, “Molecular Diagnostics: A Revolution in Progress.”
“If we can define the boundaries of molecular targets in saliva, then we can ask what the constituents in saliva are that can mark someone who has pre-diabetes or the early stages of oral cancer or pancreatic cancer — and we can utilize this knowledge for personalized medicine,” said Dr. David Wong, a senior author of the research and UCLA’s Felix and Mildred Yip Endowed Professor in Dentistry.
Wong said the test also holds promise for diagnosing Type 2 diabetes, gastric cancer and other diseases. “If you don’t look in saliva, you may miss important indicators of disease,” Wong said. “There seems to be treasure in saliva, which will surprise people.”
RNA, widely known as a cellular messenger that makes proteins and carries out DNA’s instructions to other parts of the cell, is now understood to perform sophisticated chemical reactions and is believed to perform an extraordinary number of other functions, at least some of which are unknown.
Wong’s research over the past decade has focused on identifying biomarkers in saliva. His laboratory discovered that some of the same RNA that is inside human cells are also present in saliva and can be used to detect diseases — a surprising finding, he said, because enzymes in saliva can degrade RNA, making the mouth “a hostile environment.”
The new research is a collaboration with Xinshu (Grace) Xiao, the paper’s other senior author and a UCLA associate professor of integrative biology and physiology in the UCLA College. Using state-of-the-science genomics and bioinformatics, the researchers analyzed 165 million genetic sequences.
Among the many forms of RNA are some unusual ones that live in the mouth and in cells. For example, it wasn’t known until very recently that RNA comes in a circular form; the linear form has long been known. But the UCLA scientists identified more than 400 circular RNAs in human saliva — the first discovery of circular RNA in saliva or any body fluid — including 327 forms that were previously unknown.
Circular RNA’s function in saliva is not entirely understood, although it does serve as a sponge for tiny RNA molecules called microRNAs, which bind to it.
“Circular RNAs in saliva may be protecting other RNAs,” said Xiao, who also is a member of UCLA’s Molecular Biology Institute. It’s likely, she said, that circular RNAs in saliva protect microRNAs from being degraded.
MicroRNAs, which once seemed to be little more than molecular noise, play important roles in many cell types, and have been implicated in cancers and other diseases, Xiao said. One microRNA can regulate hundreds of genes, she said.
The scientists compared microRNA levels in saliva to those in the blood and other body fluids, and found the levels of microRNA in blood and in saliva are very similar — indicating that a saliva sample would be a good measure of microRNAs in the body.
They also found that saliva contains another class of small RNAs, called piwi-interacting RNAs, or piRNAs, which are produced by stem cells, skin cells and germ cells. There are very few piRNAs in blood and most other body fluids, but Xiao’s analysis showed that piRNA are abundant in saliva. Although their function is not yet known, Xiao said they may protect the body from viral infection.
While most RNA molecules translate genetic code from DNA to make proteins, there is also a class called non-coding RNAs that does not.
“Saliva carries with it non-coding RNAs, microRNAs, piRNAs and circRNAs that are biomarkers for disease and health monitoring,” said Wong, who also is associate dean of research at the UCLA School of Dentistry. “Had we not done this collaboration, we would never know that non-coding RNAs, microRNAs, piRNAs and circRNAs exist in saliva.”
Their overriding conclusion is that saliva has tremendous medical and scientific value. In the not-too-distant future, dentists might be able to take saliva samples to analyze for a variety of diseases. And, Wong says, the research could lead to a new category of self-diagnostic devices. “This could indicate that wearable gear that informs you whether you have a disease — even before you have any symptoms — is almost here,” he said.
The scientists, both members of UCLA’s Jonsson Comprehensive Cancer Center, will continue their research, aiming to better understand the biology behind their findings, including the function of piRNAs.
“With a collaborator like Dr. Xiao, UCLA will continue to spearhead this science,” Wong said. “Now we have the capability and technology to reach deeper and study non-coding RNA, which has never been done.”
Co-authors of the research were UCLA postdoctoral scholars Jae Hoon Bahn and Qing Zhang in Xiao’s laboratory; Feng Li, an assistant researcher in Wong’s laboratory; Tak-Ming Chan, a former postdoctoral scholar in Xiao’s laboratory; Xianzhi Lin, a postdoctoral scholar in Xiao’s laboratory; and Yong Kim, a UCLA adjunct associate professor of dentistry.
The research was supported by the NIH’s National Center for Advancing Translational Sciences (award UH2TR000923) through the Extracellular RNA Communication program.

Monday, November 10, 2014

Effect of Sodium Bicarbonate–buffered Lidocaine on the Success of Inferior Alveolar Nerve Block for Teeth with Symptomatic Irreversible Pulpitis: A Prospective, Randomized Double-blind Study

Journal of Endodontics

 

Abstract

Introduction

The purpose of this prospective, randomized, double-blind study was to compare the anesthetic efficacy of buffered with nonbuffered 2% lidocaine with 1:80,000 epinephrine solution for inferior alveolar nerve (IAN) block in patients with mandibular posterior teeth experiencing symptomatic irreversible pulpitis.

Methods

Eighty adult patients diagnosed with symptomatic irreversible pulpitis of a mandibular posterior tooth were selected. The patients received 2 cartridges of either 2% lidocaine with 1:80,000 epinephrine buffered with 0.18 mL 8.4% sodium bicarbonate or 2% lidocaine with 1:80,000 epinephrine with 0.18 mL sterile distilled water using conventional IAN block injections. Endodontic access preparation was initiated 15 minutes after injection. Lip numbness was required for all the patients. Success was determined as no or mild pain on the basis of Heft-Parker visual analog scale recordings upon access cavity preparation or initial instrumentation. Data were analyzed by the t, Mann-Whitney, and chi-square tests.

Results

The success rates were 62.5% and 47.5% for buffered and nonbuffered groups, respectively, with no significant differences between the two groups (P = .381).

Conclusions

Buffering the 2% lidocaine with 1:80,000 epinephrine with 8.4% sodium bicarbonate did not improve the success of the IAN block in mandibular molars in patients with symptomatic irreversible pulpitis.

Friday, November 07, 2014

New Pink Metal Housings Add Esthetic Appeal to 3M™ ESPE™ MDI Mini Dental Implants


New housings blend more naturally with dentures

ST. PAUL, Minn. – (November 4, 2014) – For more than 10 years, dentists have been helping patients regain confidence in their full and partial dentures by using 3M™ ESPE™ MDI Mini Dental Implants for denture stabilization. Now, this market-leading solution is even more patient-pleasing, as the esthetics of the metal housings have been improved with a new pink color that helps the housings blend more naturally with dentures. The metal housings remain available in standard (MH-1), micro (MH-2) or O-cap (MH-3) designs, each of which can be used with low- or high-retention O-rings.   

The addition of pink metal housings adds to the appeal of MDI Mini Dental Implants as an alternative for patients who cannot withstand the rigors of conventional implant surgery, don’t have enough bone to allow for full-sized implants to be placed, or are seeking a lower cost option than traditional implant treatment. 

“By blending more naturally with dentures, these new pink metal housings will allow patients to eat, talk and live with comfort and confidence, said Karen Capiz, U.S. marketing manager for implants. “We are proud to continue to lead innovation in the small-diameter implant category by making the system more attractive to patients and dentists.”

Dentists may learn more about how MDI Mini Dental Implants can help build their practice by attending 1-2 day MDI Education Seminars. Introductory seminar attendees learn the minimally invasive surgical placement protocol as well as prosthetic techniques, and become prepared to stabilize full dentures using the MDI system. MDI Expanded Indications Training Seminars are intended for doctors who have attended the introductory certification MDI seminar or who have experience placing implants. 

For more information, visit 3MESPE.com/Implants.  

###


About 3M ESPE Dental 
3M ESPE is a dental product manufacturer that markets more than 2,000 dental products and services designed to help dental professionals improve their patients' oral health care. 3M ESPE is part of 3M Health Care, which provides world-class innovative products and services to help health care professionals improve the practice and delivery of patient care in medical, oral care, drug delivery and health information markets. For more information on the complete 3M ESPE line of dental products, visit the 3M ESPE website at http://www.3MESPE.com or call the 3M ESPE Technical Hotline at 1-800-634-2249. Products are available for purchase through authorized 3M ESPE distributors. 

3M and ESPE are trademarks of 3M or 3M Deutschland GmbH. Used under license in Canada. © 3M 2014. All rights reserved. 


About 3M 
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $31 billion in sales, 3M employs 89,000 people worldwide and has operations in more than 70 countries.  For more information, visit www.3M.com or follow @3MNews on Twitter.

Thursday, November 06, 2014

Medication Management for Dental Practices

DrFirst, a leading provider of healthcare IT solutions designed to improve clinical outcomes for patients, and BRS Dental, which specializes in office management software for dental practices, today announced their partnership to bring the industry’s leading e-prescribing solution, Rcopia®, and controlled substance e-prescribing with EPCS GoldSM 2.0, to dental providers.

“Our dentists frequently prescribe medications—and often the prescriptions are for painkillers, which are controlled drugs,” explains Randall Smith, Senior Vice President, Consulting and Support, for BRS Dental. “We are excited to be able to offer our dentists DrFirst’s suite of medication management solutions to upgrade the safety and efficiency of every prescription they write — all from within their dental practice management software.”

Smith continues: “BRS Dental recognizes the importance of supporting dentists with tools that help improve patient safety while increasing practice efficiency and simplifying workflow. DrFirst provides our users with Akario Mailsm, its secure and HIPAA-compliant email system, to send referrals, x-rays, images, text documents, treatment plans, and even videos to healthcare professionals.”

Adoption of e-prescribing for controlled substances is on the rise, with nearly half of pharmacies nationwide accepting e-prescriptions for controlled substances. When using EPCS, chances of prescriptions being misread or intentionally changed are minimized, drug shoppers are more easily identified, and providers are alerted to potential drug interaction or drug allergy issues at the point-of-care. In addition, the importance of EPCS is underscored by New York State’s e-prescribing mandate for both controlled and non-controlled substances to begin in March 2015.

About BRS Dental
BRS Dental is a practice management software company that emphasizes customer support and pioneering technology updates. BRS support professionals are patient, knowledgeable, and maintain detailed notes concerning the needs and goals of the practice and individuals.  BRS technology offers the same user experience on equipment located in the office or in the cloud. The company has advised small, large, and multi-location practices on information technology solutions for over three decades and is the oldest developer of dental office IT solutions. For more information, visit www.brsdental.com or call BRS Dental at 866-937-4277.

About DrFirst
DrFirst pioneers technology solutions that inform the doctor-patient point of encounter, optimizing provider access to patient information, enhancing the doctor’s clinical view of the patient, and improving care delivery and clinical outcomes. Growth is driven by a commitment to innovation, security, and reliability across a wide array of services, including medication management, medication adherence, and secure communication and collaboration. DrFirst is proud of its track record of service to more than 300 EMR/EHR/HIS vendors and an extensive network of providers, hospitals, and patients. For more information, please visit www.drfirst.com.


Wednesday, November 05, 2014

Dental Implant Failure Quick Poll Results from National Dental PBRN


Dental implant failures are rare events. The contributory role of the patient's medical conditions and medication(s) in dental implant failure is not fully understood. Drs. Subramanian and Quek from Rutgers were interested in investigating whether anti-resorptive therapies (e.g., bisphosphonates) contribute to dental implant failures. The survey questions were geared towards identifying early and delayed implant failures in conjunction with systemic conditions such as diabetes, diseases such as osteoporosis and cancer that necessitated anti-resorptive therapy. Implant failure was defined as 'implant mobility in rotational, axial or horizontal direction' in the presence/ absence of pain or discomfort and radiographic evidence of peri-implant bone loss.
Among 277 responders, 167 (nearly 60%) reported implant failures.Nearly a third of all implant failures were observed in the setting of systemic conditions in the patients, warranting a closer look at these entities. Anti-resorptive therapy has been reported by nearly 10-15% of the responders as associated with early and delayed dental implant failures. It was notable that over 120 of the nearly 170 responders who reported implant failures expressed their willingness to be contacted for additional information, important in order to build on this preliminary data. As the longevity of implants in an Implant Registry Study is explored further in the network, the results of this quick poll will help inform that workgroup.
Click here to view the table with the summary of results.

Tuesday, November 04, 2014

Independent Study Recognizes Extreme Low Dose Capabilities of Carestream Dental’s CS 9300 Low Dose Mode


ATLANTA—Recent studies have confirmed that the CS 9300 family of cone beam computed tomography (CBCT) systems can provide 3D exams at up to 85 percent lower dose than traditional 2D panoramic imaging. The research, conducted by John Ludlow, D.D.S., of the University of North Carolina’s School of Dentistry, Chapel Hill, found that 3D images captured using the Low Dose Mode for a 5x5 cm adult exam provides an effective dose of just 3 microsieverts (µSv)1.
Dose-saving algorithms and noise reduction processing enables the new Low Dose Mode to drastically reduce the dose and scanning time of the CS 9300—between 73 and 95 percent as compared to standard acquisition mode2—while maintaining diagnostic image quality. Low Dose Mode is available for 17x11 cm down to 5x5 cm scans and covers multiple applications such as implant planning; follow-up exams for orthognathic, maxillofacial surgery or implant; analyzing skeletal symmetry; assessing airways; evaluating impacted teeth and supernumeraries; and pediatric examinations.
“We all naturally absorb about 2,400 µSv of radiation per year from our surroundings,” Ed Shellard, D.M.D, chief commercial officer, Carestream Dental, said. “Low Dose can optimize the dosage to just 3 µSv for a 5x5 cm adult exam, or less than half a day’s equivalent background radiation. This is ideal for pediatric or follow-up examinations, which allows the practitioner to prescribe the image quality required while adhering even more to the ALARA [As Low as Reasonably Achievable] Principle.” 
An additional benefit of the new Low Dose Mode is that existing units in the CS 9300 family can easily be retrofitted with the module, so that doctors can ensure they’re treating their patients with the lowest dosage possible.
“We want doctors to rest assured that they’re always using the safest and most advanced technology when treating their patients with Carestream Dental equipment,” David Roudergues, director of U.S. dental equipment, product line manager, Carestream Dental, said. “The Low Dose module allows practices to easily update their existing equipment and operating systems, without the burden of purchasing a whole new unit.”
Along with reduced radiation, the CS 9300 offers exceptional 3D imaging technology and leading 2D digital panoramic imaging with variable focal trough technology. One-shot cephalometric imaging is available as an optional feature. The system produces an image resolution of up to 90 µm with 1:1 accuracy, delivering superior diagnostic detail. Additionally, the CS 9300 features medium to large field 3D imaging with seven selectable fields of view, ranging from 5 cm x 5 cm to 17 cm x 13.5 cm. These fields of view support a wide variety of clinical applications, such as implantology, oral and maxillofacial surgery, orthognathics and orthodontics.
The CS 9300 family also includes the CS 9300 Select, which offers medium field 3D imaging with four fields of view. As with the CS 9300, the CS 9300 Select is also available with an optional cephalometric arm. Both the CS 9300 and the CS 9300 Select can be easily upgraded with the Low Dose module.  
For more information about the Low Dose imaging or the CS 9300 family, please call 1.800.944.6365 or visit www.carestreamdental.com.
1 Based on studies conducted by John B. Ludlow, University of North Carolina, School of Dentistry: Dosimetry of CS 8100 CBCT Unit and CS 9300 Low-Dose Protocol, August 2014; Dosimetry of the Carestream CS 9300 CBCT unit, June 2011. 85% reduction (3µSv) found in 5x5 cm adult exams; exact dose reduction varies based on field of view and ranges from 0% to 85%.  
2 Based on study conducted by John Ludlow, University of North Carolina, School of Dentistry, Dosimetry of CS 8100 CBCT Unit and CS 9300 Low-Dose Protocol, September 2014

About Carestream Dental
Carestream Dental provides industry-leading imaging, CAD/CAM, software and practice management solutions for dental and oral health professionals. With more than 100 years of industry experience, Carestream Dental products are used by seven out of 10 practitioners globally and deliver more precise diagnoses, improved workflows and superior patient care. For more information or to contact a Carestream Dental representative, call 800.944.6365 or visit www.carestreamdental.com.

About Carestream Health
Carestream is a worldwide provider of dental and medical imaging systems and IT solutions; X-ray imaging systems for non-destructive testing and advanced materials for the precision films and electronics markets. For more information about the company’s broad portfolio of products, solutions and services, please contact your Carestream representative, call 888.777.2072 or visit www.carestream.com.

Follow us online: Facebook IconTwitter IconLinkedIn IconYouTube IconGoogle+ IconBlog IconMedia Room Icon